The first test of Recursion's Exscientia move
The combined company's MALT1 inhibitor has started phase 1.
The month ahead: June’s upcoming events
Crunch time approaches for UroGen.
Relay pulls ahead of Lilly
A pivotal trial of the group’s mutant-selective PI3Kα inhibitor, RLY-2608, will start in July.
Pfizer doubles down on PD-L1 conjugates
PF-08046037 joins PF-08046054 in clinical development.
Avistone’s Met challenge
The company starts a China phase 3 of andamertinib in EGFR-mutant, Met-amplified NSCLC.
Crispr moves ahead in GPC3
RPCAR01 starts a phase 1 study, albeit one sponsored by academics.
